|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
L01XE17
|
|
gptkbp:brand
|
Inlyta
|
|
gptkbp:CASNumber
|
319460-85-0
|
|
gptkbp:chemicalClass
|
indazole derivative
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
2.5-6.1 hours
|
|
gptkbp:hasMolecularFormula
|
C22H18N4OS
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits VEGF receptors
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2C19
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
~99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521686
6450551
DB06626
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hand-foot_syndrome
diarrhea
fatigue
hypertension
dysphonia
|
|
gptkbp:target
|
gptkb:VEGFR-1
gptkb:VEGFR-2
gptkb:VEGFR-3
|
|
gptkbp:UNII
|
32CM1I371D
|
|
gptkbp:usedFor
|
gptkb:renal_cell_carcinoma
|
|
gptkbp:bfsParent
|
gptkb:NCT03400917
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Axitinib
|